Podcast: This Week in Managed Care—Step Therapy in Medicare Advantage and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care stories included, CMS allowing step therapy in Medicare Advantage plans in a bid to allow for drug price negotiation; larger practices with more resources, technology and care management processes have higher readmission rates than smaller practices; studies find that empagliflozin also reduces liver fat in patients with diabetes and nonalcoholic fatty liver disease.

To listen, login to the website.

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg

Listen above or through one of these podcast services:

CMS Will Allow Medicare Advantage Plans to Use Step Therapy to Negotiate Drug Prices

CMS Approves Extra Payments for CAR T, Increases Other Payments in Final Rule

Larger Practices Spend More on, Have Higher Readmission Rates for Medicare Beneficiaries

Liquid Biopsy Identifies Patients More Likely to Benefit From Immunotherapy in NSCLC

Studies Point to Empagliflozin as First Choice for Fatty Liver Disease in T2D

Discussing Increased Prevalence of NAFLD and NASH, and the Current Lack of Treatments

Read more about the stories in this podcast:

Related Videos
Screenshot of Sancy Leachman, MD, PhD, smiling
Jeremy Wigginton, MD
Manmeet Ahluwalia, MD, MBA.
Nicolas Ferreyros, BA, managing director, The Community Oncology Alliance
Susan Sabo-Wagner, MSN, RN, OCN, Oncology Consultants
Samyukta Mullangi, MD, MBA.
Manmeet Ahluwalia, MD, MBA.
Jeff Hunnicutt, CEO, Highlands Oncology Group
Sigrun Hallmeyer, MD, Advocate Health
Kevin Davies, PhD, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing
Related Content
© 2023 MJH Life Sciences
AJMC®
All rights reserved.